Skip to main content
. 2022 Nov 29;14(23):5867. doi: 10.3390/cancers14235867

Figure 2.

Figure 2

(A): Significantly higher concentrations of Nectin-4 in FIGO I/II (26 cases) compared to FIGO III/IV (104 cases), Mann–Whitney test * (p = 0.043). (B): No significant difference in HB-EGF levels between early and advanced FIGO stages, Mann–Whitney test (p = 0.59). (C): Nectin-4 levels were significantly increased in FIGO I/II stages (26 cases) vs. 100 healthy controls, Mann–Whitney test **** (p < 0.0001). (D): Significantly elevated HB-EGF levels between control group vs. early FIGO I/II stages, Mann–Whitney test * (p = 0.025). (E): Receiver operating characteristic (ROC) of Nectin-4. (F): ROC curve of HB-EGF. (G): Significantly elevated Nectin-4 levels in 72 patients without macroscopic tumor remnant (R0) compared to 56 patients with macroscopic tumor remnant (R1), Mann–Whitney test ** (p = 0.0021). (H): No increased HB-EGF levels between R0 and R1. Mann–Whitney test (p = 0.74). All panels except for E and F show boxplots.